Product Description
Vocacapsaicin is a novel prodrug of trans-capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide) being developed as a nonopioid, long-lasting, site-specific treatment for postsurgical pain management. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/35128722/)
Mechanisms of Action: TRPV1 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Concentric Analgesics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Pain, Postoperative|Metatarsal Valgus|Bunion|Hallux Valgus
Phase 1: Bunion|Hallux Valgus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CA-PS-209 | P2 |
Completed |
Pain, Postoperative |
2021-06-15 |
|
| Vocacapsaicin | P2 |
Completed |
Pain, Postoperative |
2020-10-26 |
|
| CA-PS-205 | P2 |
Completed |
Hallux Valgus|Metatarsal Valgus|Bunion |
2019-07-02 |
|
| CA-PS-204 | P2 |
Completed |
Pain, Postoperative |
2019-05-16 |